

1 **Impact of three ampicillin dosage regimens on selection of ampicillin**
2 **resistance in *Enterobacteriaceae* and excretion of *bla*_{TEM} genes in swine feces**

3
4 D. Bibbal,¹ V. Dupouy,¹ J.P. Ferré,¹ P.L. Toutain,¹ O. Fayet,² M.F. Prère,² and A. Bousquet-
5 Mélou^{1*}

6
7 UMR181 Physiopathologie et Toxicologie Expérimentales, INRA, ENVT, Ecole Nationale
8 Vétérinaire de Toulouse, 23 Chemin des Capelles, BP 87 614, 31076 Toulouse Cedex 3,
9 France¹.

10 UMR5100 Microbiologie et Génétique Moléculaires, CNRS, UPS, Laboratoire de
11 Microbiologie et Génétique Moléculaires, Université Paul Sabatier, 118 route de Narbonne,
12 31062 Toulouse Cedex, France².

13
14
15 * Corresponding author. Mailing address: UMR181 Physiopathologie et Toxicologie
16 Expérimentales, INRA, ENVT, Ecole Nationale Vétérinaire de Toulouse, 23 Chemin des
17 Capelles, BP 87 614, 31076 Toulouse Cedex 3, France. Phone: 33 (0) 561 193 925. Fax: 33
18 (0) 561 193 917. E-mail: a.bousquet-melou@envt.fr

19 **ABSTRACT**

20 The aim of this study was to assess the impact of three ampicillin dosage regimens on
21 ampicillin resistance among *Enterobacteriaceae* recovered from swine feces using phenotypic
22 and genotypic approaches. Phenotypically, ampicillin resistance was determined from the
23 percentage of resistant *Enterobacteriaceae* and MICs of *E. coli* isolates. The pool of
24 ampicillin resistance genes was also monitored by quantification of *bla*_{TEM} genes, which code
25 for the most frequently produced β -lactamases in Gram-negative bacteria, using a newly-
26 developed real-time PCR assay. Ampicillin was administered intramuscularly and by oral
27 route to fed or fasted pigs for 7 days at 20 mg/kg. The average percentage of resistant
28 *Enterobacteriaceae* before treatment was between 2.5% and 12% and *bla*_{TEM} genes quantities
29 were below 10^7 copies/g of feces. By days four and seven, the percentage of resistant
30 *Enterobacteriaceae* exceeded 50% in all treated groups, with some highly resistant strains
31 (MIC>256 μ g/mL). In the control group, *bla*_{TEM} genes quantities fluctuated between 10^4 - 10^6
32 copies/g of feces, whereas they fluctuated between 10^6 - 10^8 and 10^7 - 10^9 copies/g of feces for
33 intramuscular and oral routes, respectively. Whereas phenotypic evaluations did not
34 discriminate between the three ampicillin dosage regimens, *bla*_{TEM} genes quantification was
35 able to differentiate between the effects of two routes of ampicillin administration. Our results
36 suggest that fecal *bla*_{TEM} genes quantification provides a sensitive tool to evaluate the impact
37 of ampicillin administration on the selection of ampicillin resistance in the digestive
38 microflora and its dissemination in the environment.

39 INTRODUCTION

40

41 The major mechanism of resistance to β -lactam antibiotics in Gram-negative bacteria
42 results from the production of β -lactamases. Most of these are coded by the plasmid-mediated
43 *bla*_{TEM-1} gene (19, 28). The continuous introduction of new β -lactam antibiotics with different
44 activity spectra in human medicine has led to the selection of β -lactamase mutations, which
45 confer resistance to the newly-developed β -lactam antibiotics (25). β -lactam antibiotics are
46 also used in veterinary medicine where they contribute to the selective pressure that leads to
47 the emergence and diffusion of intestinal bacteria harboring resistance genes. Thus,
48 commensal bacteria in the gut form a reservoir of antibiotic resistance genes potentially
49 transmissible to humans *via* the food-chain and the environment (27, 29, 34).

50 Antimicrobial resistance in food animals deserves special attention. One of the most
51 heavily medicated sectors is pig-farming, world-wide antibiotic consumption in pigs
52 accounting for 60% of the antibiotics used in animals (10). A relationship has been
53 demonstrated between the high use of antimicrobials in pig herds and increased occurrence of
54 resistant bacterial strains in their digestive tracts (4, 13, 34, 37). When antibiotics are
55 administered to pigs, both the level and time-development of antibiotic exposure of the
56 intestinal microflora are dependent on the mode of drug administration (38). This exposure is
57 a key determinant of antibiotic resistance development in the gut flora, and the relation
58 between antibiotic dosage regimen and resistance merits attention. The impact of different
59 antibiotic dosage regimens on the emergence of resistance must be evaluated by appropriate
60 quantitative indicators of the resistance level. Traditionally, this has involved phenotypic
61 methods that measure bacterial antibiotic susceptibility (32). In addition, quantitative PCR has
62 been recommended for resistance genes surveillance because i) it is sensitive ii) unambiguous

63 standard curves can be used to quantify the resistance genes from various matrices and iii) no
64 bacterial cultivation is required (15, 20, 31, 39).

65 The aim of the present study was both to develop and validate a real-time PCR assay
66 to quantify fecal *bla*_{TEM} genes in swine stools, and to explore the impact of three different
67 ampicillin dosage regimens on fecal ampicillin resistance in swine using different indicators.
68 Ampicillin resistance was evaluated by quantifying the *bla*_{TEM} genes in feces by real-time
69 PCR assay associated with two conventional phenotypic methods based on determination of
70 the MICs of *E. coli* isolates and the percentage of resistant *Enterobacteriaceae*. The three
71 dosage regimens tested were: intramuscular route, oral route in fed and oral route in fasted
72 swine.

73

74 MATERIALS AND METHODS

75 **Study design and sample collection.** Eighteen 7-week old, commercial healthy
76 piglets, that had never received antibiotics, were used. They were housed separately in
77 individual pens throughout all the experiments. A meal was given twice daily and water was
78 provided *ad libitum*. Ampicillin was administered once a day at 20 mg/kg for seven days
79 (from day 0 to day 6) following three modalities: intramuscular route, oral route in fasted pigs
80 or oral route in fed pigs. The design schedule consisted of three successive series of 6 animals
81 receiving ampicillin treatments as follows: intramuscular (n=2), oral route in fed conditions
82 (n=2), control without treatment (n=2) in the first series; intramuscular (n=2), oral route in
83 fasted conditions (n=2), control without treatment (n=2) in the second series; oral route in fed
84 conditions (n=2), oral route in fasted conditions (n=2), control without treatment (n=2) in the
85 third series. Six pigs were used in the control group and 4 pigs in each ampicillin treatment
86 group. Intramuscular injections of ampicillin sodium (Ampicilline Cadril, Laboratory
87 Coophavet, Ancenis, France) were administered in the neck. For oral routes, a medicinal
88 premix (Ampicilline 80 Porc Franvet, Laboratory Franvet, Segré, France) was dissolved in
89 water and administered by gastric intubation. Fasted swine were starved 16 hours before
90 ampicillin administration and fed 4 hours after ampicillin administration. Ampicillin was
91 administered to fed pigs just at the end of their morning meal.

92 For phenotypic evaluation of ampicillin resistance, fecal samples were taken from
93 each pig, by digital manipulation or immediately after spontaneous defecation, at days 0
94 (before ampicillin administration), 1, 4, and 7. The samples were immediately transferred to
95 the laboratory and the *Enterobacteriaceae* were counted. For the quantification of *bla*_{TEM}
96 genes in feces by real-time PCR, feces of each pig were collected two or three times before
97 the treatment. The value given for day 0 is the mean of these samplings. Feces were then
98 collected each day from day 1 to day 7. Samples were obtained as already described. Two

99 hundred mg of feces from each sample were frozen in liquid nitrogen and stored at -80°C
100 until assayed.

101 **Phenotypic evaluation of ampicillin resistance.** Feces (5 g) from each pig were
102 homogenized with 45 mL of peptone water, including 30% of glycerol, with a BagMixer
103 (Interscience, St Nom, France). Ten-fold serial dilutions of the filtrate were prepared and 100
104 µL of the dilutions were spread on MacConkey plates (AEB 151602, AES, Ker Lann, France)
105 containing 0 and 16 µg/mL of ampicillin. MacConkey agar is classically used for selective
106 growth of *Enterobacteriaceae* (7, 8, 11, 30). *Enterobacteriaceae* growing in the presence of
107 16 µg/mL of ampicillin were classified as resistant. This concentration corresponds to the
108 MIC breakpoint value (MIC ≥ 32 µg/mL) proposed by the CLSI (23) and the French Society
109 of Microbiology (<http://www.sfm.asso.fr>). The plates were incubated at 37°C for 24 h.
110 *Enterobacteriaceae* counts from both plates were used to calculate the percentage of resistant
111 *Enterobacteriaceae* at each sampling time.

112 For each sample, 20 colonies were randomly picked on the MacConkey plates without
113 ampicillin and stored at -80°C until assayed. These colonies were considered as *E. coli* on the
114 basis of β-glucuronidase production using TBX agar (Tryptone Bile X-glucuronide agar, AES
115 laboratoire, Bruz, France) (14). Only a few colonies were β-glucuronidase negative. All β-
116 glucuronidase negative isolates and a portion of β-glucuronidase positive isolates were tested
117 by the API 20E *Enterobacteriaceae* identification system (bioMérieux, Marcy l'Etoile,
118 France) to confirm their identification. For MICs determination, ampicillin susceptibility was
119 tested by microdilution broth dilution method according to the recommendations reported by
120 the CLSI (22). The control strain was *E. coli* ATCC 25922.

121 **Bacteria and growth conditions.** *E. coli* JS238[pOFX326], the plasmid of which
122 carries a monocopy of the target gene *bla*_{TEM-1}, was used to optimize real-time PCR, assess

123 sensitivity and generate quantification standards. The strain was cultured in Mueller-Hinton
124 broth containing ampicillin at the concentration of 50 µg/mL at 37°C overnight.

125 **DNA extraction.** pOFX326 was purified with the QIAprep Spin Miniprep (Qiagen,
126 Hilden, Germany). Quality was assessed by migration on gel electrophoresis in 1% agarose,
127 after digestion with *Hind*III and concentration was assessed by spectrophotometry at 260 nm.
128 The QIAamp DNA Stool kit (Qiagen, Hilden, Germany) was used to extract DNA from feces
129 according to manufacturer's recommendations. For each series of extractions, a positive
130 control and a negative control were co-extracted and subjected to real-time PCR.

131 **Design of primers.** The PCR primers were designed with Primer 3 and Oligo
132 Analyser. The specificity of the sequence was further checked against all the available
133 GenBank DNA sequences. The forward and reverse primers chosen for *bla*_{TEM} genes
134 quantification were 5'-TTCCTGTTTTTGCTCACCCAG-3' and 5'-
135 CTCAAGGATCTTACCGCTGTTG-3', respectively. These primers amplify a 112 bp
136 segment of the *bla*_{TEM-ID} gene (GeneBank accession number AF 1888200) from nucleotide
137 positions 270 to 382. A 100% homology was demonstrated with 130 *bla*_{TEM} genes for which
138 the nucleotide sequence was available, except for TEM-60.

139 **Real-time PCR assay.** The PCR amplification was performed in a 25 µL reaction
140 mixture with a SYBR Green PCR Core Reagents kit (Perkin Elmer Biosystems, Foster City,
141 USA). The reaction mixture contained 5 µL of test DNA solution, 2.5 µL of 10X SYBR
142 Green PCR Buffer, 1.6 µL of a deoxynucleoside triphosphate solution (2.5 mM each of
143 dATP, dCTP and dGTP and 5 mM of dUTP), 0.25 µL of each primer (20 µM), 4 µL of 25
144 mM MgCl₂, 11.275 µL of Ultra Pure Water (Qbiogene, Montréal, Canada) and 0.125 µL of
145 AmpliTaq Gold® DNA Polymerase, LD (5 U/µL) (Perkin Elmer Biosystems). Amplification
146 was performed using a GeneAmp® PCR System 5700 thermocycler (Perkin Elmer
147 Biosystems) with the following conditions: 95°C for 10 min followed by 45 cycles of 15

148 seconds at 95°C and 1 minute at 60°C. A standard curve with three replicates of the control
149 plasmid pOFX326 diluted in Tris-EDTA buffer was generated for each PCR assay. All
150 sample PCRs were done in duplicate. The samples were checked for absence of background
151 levels of PCR-inhibiting compounds by spiking DNA extracted from the samples with target
152 DNA and subjecting these spiked DNA samples to real-time PCR both undiluted and diluted
153 (1:10).

154 The impact of DNA fecal environment on amplification sensitivity and performance was
155 assessed by comparing standard curves obtained with the control plasmid diluted in Tris-
156 EDTA or in swine fecal DNA. The accuracy and reproducibility of the entire assay (from
157 DNA extraction to real time PCR analysis) was measured by spiking 200 mg of feces with an
158 overnight culture of *E. coli* JS238[pOFX326]. Five aliquots per day were subjected to DNA
159 extraction on three different days. The extraction recovery rate was calculated. It was checked
160 to be the same for different concentrations of *bla*_{TEM} genes in feces by spiking fecal samples
161 with 10-fold serial dilutions of an overnight culture of *E. coli* JS238[pOFX326]. These
162 samples were subjected to DNA extraction and then to real-time PCR.

163 **Statistical analysis.** Statistical analysis was performed using Systat 10 (Systat
164 Software Inc., Richmond, CA, USA). Changes in the level of ampicillin resistance were
165 analyzed using a generalized linear mixed-effects model with the following equation:

$$166 \quad Y_{ijk} = \mu + M_i + D_j + A_k|_{M_i} + M^*D_{ij} + \epsilon_{ijk},$$

167 where Y_{ijk} is the measure of resistance for pig k undergoing ampicillin administration with
168 modality i at day j , μ the overall mean, M_i the differential effect of treatment i , D_j the
169 differential effect of day j , M^*D_{ij} the corresponding interaction, $A_k|_{M_i}$ the differential effect
170 of animal k nested within treatment i and ϵ_{ijk} an error term. Y , the measure of resistance, was
171 monitored in various ways. For the phenotypic evaluation of resistance, Y was the log-
172 transformed percentage of the resistant *Enterobacteriaceae* population or the log-transformed

173 percentage of *E. coli* isolates with MIC > 16 µg/ml. For the genotypic evaluation, Y was the
174 log-transformed quantity of *bla*_{TEM} genes. Multiple comparisons were performed using the
175 Tukey test. The selected level of significance was P<0.05.

176 RESULTS

177

178 **Validation of the PCR assay.** In order to construct calibration curves and determine
179 the specificity and sensitivity of the primers in swine fecal DNA, the control plasmid
180 pOFX326 was diluted in Tris-EDTA buffer and in swine fecal DNA. Each dilution was
181 subjected to real time PCR and the amplifications were repeated four times. Melting-curve
182 analysis of the control plasmid, diluted either in Tris-EDTA buffer or in swine fecal DNA,
183 showed specific amplification with a PCR amplicon at a T_m value of 81°C (data not shown).
184 Despite the use of highly purified AmpliTaq Gold® DNA Polymerase, analysis of the Ultra-
185 Pure Water melting-curves revealed contamination and thus restricted the PCR quantification
186 limit (data not shown). Fig. 1 shows the two standard curves: the relation between Ct
187 (threshold cycles) values and the logarithm of bla_{TEM} concentration was linear from 10 to 10^6
188 copies/ μ L. The determination coefficients (r^2) were of 0.996 in Tris-EDTA and 0.985 in
189 swine fecal DNA. The closeness between these standard curves indicated that the complex
190 fecal DNA environment did not affect amplification sensitivity or performance. The intra- and
191 inter-day coefficients of variation of the entire assay (from DNA extraction to real time PCR
192 analysis) were 16.7% and 18.2%, respectively. The extraction recovery rate was 70-113%
193 (mean 98.5 %). This was checked to be the same for different concentrations of bla_{TEM} genes
194 in feces by spiking fecal samples with 10-fold serial dilutions of an overnight culture of *E.*
195 *coli* JS238[pOFX326]. The correlation between bla_{TEM} copy number/g feces and dilution
196 factors of the JS238[pOFX326] solution was high (with a determination coefficient,
197 $r^2=0.904$). Thus the extraction yields for different concentrations of *E. Coli* JS238[pOFX326]
198 in feces were similar. Overall data demonstrated that this PCR analysis was suitable for
199 quantification of bla_{TEM} genes in swine feces from 10 to 10^6 copies/ μ L of eluate of extracted
200 DNA, which corresponds to 10^4 to 10^9 copies/g of feces.

201 **Phenotypic evaluation of ampicillin resistance.** Average percentages of ampicillin-
202 resistant *Enterobacteriaceae* for each treatment group are given in Fig. 2a. The average
203 percentage of resistant *Enterobacteriaceae* ranged from 0.9% to 12% before ampicillin
204 administration. On the first day of treatment, it rose to 26% for the intramuscular route and to
205 40% and 49% for the oral routes in fed and fasted pigs respectively. By days 4 and 7, the level
206 of resistance exceeded 50% in all treated groups. In contrast, the level of resistance in the
207 control group remained below 13% at all times. Treated animals excreted significantly higher
208 percentages of resistant *Enterobacteriaceae* compared to the control group ($P<0.05$).
209 However, no significant differences were observed between the three modes of drug
210 administration ($P>0.05$). Furthermore, Fig. 2a shows the high inter-individual variability
211 within each group.

212 Ampicillin resistance was also monitored from the percentage of resistant *E. coli*
213 isolates for each treatment group (Fig. 2b). The average percentage of resistant *E. coli* ranged
214 from 1% to 38% before ampicillin administration. At day 1 of treatment, about 70% of
215 isolates were resistant, whatever the mode of drug administration. By days 4 and 7, nearly all
216 the isolates, whatever the dosage regimen, were resistant. In contrast, the percentages of
217 resistant *E. coli* remained below 36% in the control group. Statistical analysis indicated that
218 oral administration in fed pigs led to a higher fecal excretion of resistant *E. coli* than in
219 control pigs ($P<0.05$). The two other dosage regimens did not differ significantly from the
220 control group due to the great heterogeneity of the control group data ($P>0.05$). High inter-
221 individual variability also existed within each ampicillin-treated group.

222 **Genotypic evaluation of ampicillin resistance.** Ampicillin resistance in feces was
223 measured by *bla*_{TEM} genes quantification using the validated PCR assay. *bla*_{TEM} genes copy
224 numbers per gram of wet feces were measured on each day of treatment for each pig (Fig. 3).
225 The baseline values for all pigs were below 10^7 copies/g of feces. *bla*_{TEM} quantities increased

226 after ampicillin administration. The between-day fluctuations for a given animal were large.
227 The *bla*_{TEM} quantities for the oral routes fluctuated between 10⁷ and 10⁹ copies/g of feces, but
228 only between 10⁵ and 10⁸ copies/g of feces for the intramuscular route. Two fed pigs treated
229 by oral route excreted the highest *bla*_{TEM} quantities with values above 10⁹ copies/g of feces.
230 The *bla*_{TEM} quantities for the control group were lower than those of the three ampicillin-
231 treated groups and fluctuated between 10⁴ and 10⁶ copies/g of feces.

232 Fig. 4 shows the mean quantities of *bla*_{TEM} genes for each dosage regimen. Statistical
233 analysis indicated that all ampicillin treatments had a significant effect on the excretion of
234 *bla*_{TEM} genes compared to the control group ($P < 0.001$). Moreover, oral administration in fed
235 pigs led to a significantly higher excretion of *bla*_{TEM} genes than intramuscular administration
236 ($P < 0.05$).

237 **Comparisons of real time PCR assessments and phenotypic plate assays.** We
238 investigated the agreement between resistant *Enterobacteriaceae* counts and *bla*_{TEM}
239 concentrations. Fig. 5 shows a significant correlation (with a determination coefficient,
240 $r^2 = 0.67$) between the quantities of *bla*_{TEM} genes and the counts of ampicillin-resistant
241 *Enterobacteriaceae*.

242

243 **DISCUSSION**

244 The aim of this study was to explore the impact of three ampicillin dosage regimens
245 on the selection of ampicillin resistance in swine feces. Three indicators of ampicillin
246 resistance *i.e.* two classical phenotypic methods and a new genotypic method allowing
247 quantification of *bla*_{TEM} genes in feces were selected. The results, whichever resistance
248 indicator was used, indicated that the different modes of ampicillin administration led
249 immediately (day one of treatment) to a large increase in the level of ampicillin resistance in
250 the fecal microflora. In addition, the results suggested that the quantitative PCR of fecal
251 *bla*_{TEM} genes might be a promising tool to quantify the digestive reservoir of *bla*_{TEM} genes and
252 evaluate the impact of β -lactam administration on the selection of ampicillin resistance in the
253 gut microflora.

254 Antibiotic impact on the gut microflora is generally measured by phenotypic
255 evaluation of antibiotic resistance on a limited bacterial population, either using isolates of
256 indicator bacteria or families of bacteria. *E. coli* and *Enterobacteriaceae* are good candidates
257 for studies of the antibiotic resistance level of the fecal flora and are commonly used for this
258 in pigs (32). These bacteria are easily culturable and their isolation is facilitated by specific
259 culture media. In the present experiment, results obtained with the two phenotypic indicators
260 of ampicillin resistance implied that all treatments had a similar negative impact on the gut
261 microflora with the emergence of a high level of resistance at all three dosage regimens.
262 These results are consistent with those of previous studies demonstrating that ampicillin
263 treatment could have a marked effect on the level of resistance in intestinal microbiota of
264 several species (9, 21, 33). Nevertheless, the phenotypic indicators commonly used to assess
265 antibiotic resistance exhibit methodological features that impact both their metrological
266 performances and relevance. Firstly, the selected indicator bacteria must be cultured and the
267 reliability of results has been questioned due to considerable variation originating from the

268 culture medium, bacterial inoculum, antibiotic preparation and incubation conditions (26).
269 Secondly, the isolates might not be representative of the whole population of bacteria (6).
270 These limits impair the sensitivity and precision of phenotypic indicators for the assessment
271 of resistance levels and have prompted investigators to develop molecular techniques as
272 alternatives, in particular quantitative PCR (15, 20, 31, 39).

273 Molecular techniques can be used to reveal the presence of genetic determinants without
274 bacterial cultivation and irrespective of the bacterial species carrying these genetic
275 determinants (5, 35). However, a requisite to this approach is the knowledge of the underlying
276 resistance mechanisms, and when few genes are involved in resistance, they may provide
277 candidates for resistance markers (3). *bla*_{TEM} genes code for the most commonly encountered
278 β -lactamases in Gram-negative bacteria (24). We therefore developed and validated a real-
279 time PCR assay to quantify *bla*_{TEM} genes in swine feces. This PCR assay was suitable for
280 quantification of *bla*_{TEM} genes from 10^4 to 10^9 copies/g of feces.

281 Examination of the agreement between resistant *Enterobacteriaceae* counts and *bla*_{TEM}
282 concentrations revealed a significant correlation between the quantities of *bla*_{TEM} genes and
283 the counts of ampicillin-resistant *Enterobacteriaceae*. The observed scatter is probably due
284 partly to the inaccuracy of both techniques and to the fact that amplified *bla*_{TEM} genes may be
285 harbored by bacteria other than *Enterobacteriaceae* (16).

286 During our experiment to monitor *bla*_{TEM} genes excretion, we found that treated pigs
287 excreted more *bla*_{TEM} genes than control pigs. Moreover, as in the phenotypic evaluations, the
288 fecal excretion of *bla*_{TEM} genes showed large individual day-to-day fluctuations. As indicated
289 above, these fluctuations were correlated with counts of ampicillin-resistant
290 *Enterobacteriaceae*. Similarly, Belloc *et al.* (2) studied the effect of quinolone treatment on
291 selection and persistence of quinolone-resistant *E. coli* in swine fecal flora and observed great
292 variability both in the percentage of resistant strains and pattern of emergence of resistance. In

293 the present study, despite the great variability and the small number of pigs *per* mode of
294 treatment, at least two of the three modes of drug administration (i.e. intramuscular route and
295 oral route in fed pigs) could be differentiated by quantifying the *bla*_{TEM} genes excreted in
296 feces, but not by phenotypic evaluation. These results imply that a genotypic indicator can be
297 used advantageously as a complement to phenotypic approaches to quantitatively evaluate the
298 intestinal reservoir of resistance genes. For example, *bla*_{TEM} genes quantification has already
299 been used to evaluate ampicillin-induced selective pressure on the gut microbiota in dogs
300 (15).

301 Our results, showing that oral administration of ampicillin in fed pigs was associated
302 with the highest excretion level of fecal *bla*_{TEM} genes, are consistent with both our
303 pharmacokinetic measurements (not shown) and published data. These latter indicate that β -
304 lactam absorption following oral administration is largely incomplete in pigs (1, 17) and that
305 feeding decreases β -lactam absorption in pigs as in dogs (18) and humans (36). As a
306 consequence, these expected high concentrations of unabsorbed ampicillin in the intestine are
307 likely to exert great pressure on the gut microflora, and this all the more if ampicillin is
308 administered to fed pigs. Following intramuscular administration, ampicillin can gain access
309 to the gastrointestinal lumen by biliary excretion (12), which explains why the intramuscular
310 route was also associated with an increase in fecal *bla*_{TEM} genes excretion. Thus the
311 pharmacokinetic profiles of the three modes of ampicillin administration tested in the present
312 study were apparently different and resulted in different intestinal exposures.

313 In conclusion, our study indicates that fecal *bla*_{TEM} genes quantification might be a
314 useful tool to evaluate and discriminate the impact of different modes of ampicillin
315 administration on the gut microflora. In the future, this quantitative tool might help to
316 quantify the flux of resistance genes in epidemiological investigations.

317 **ACKNOWLEDGMENTS**

318 This work was supported by the Conseil Régional de Midi-Pyrénées grant 03011987.

319 We thank Nathalie Arpaillange and Nadine Gauthier for their technical support and Jean-

320 Pierre Gau, Patrice Rouby, Joseph Maligoy and Jean Denjean for taking care of the animals.

321 **REFERENCES**

322 1. **Agerso, H., and C. Friis.** 1998. Bioavailability of amoxycillin in pigs. *J Vet*
323 *Pharmacol Ther* **21**:41-6.

324 2. **Belloc, C., D. N. Lam, J. L. Pellerin, F. Beaudreau, and A. Laval.** 2005. Effect of
325 quinolone treatment on selection and persistence of quinolone-resistant *Escherichia*
326 *coli* in swine faecal flora. *J Appl Microbiol* **99**:954-9.

327 3. **Bergeron, M. G., and M. Ouellette.** 1998. Preventing antibiotic resistance through
328 rapid genotypic identification of bacteria and of their antibiotic resistance genes in the
329 clinical microbiology laboratory. *J Clin Microbiol* **36**:2169-72.

330 4. **Blake, D. P., R. W. Humphry, K. P. Scott, K. Hillman, D. R. Fenlon, and J. C.**
331 **Low.** 2003. Influence of tetracycline exposure on tetracycline resistance and the
332 carriage of tetracycline resistance genes within commensal *Escherichia coli*
333 populations. *J Appl Microbiol* **94**:1087-97.

334 5. **Courvalin, P.** 1991. Genotypic approach to the study of bacterial resistance to
335 antibiotics. *Antimicrob Agents Chemother* **35**:1019-23.

336 6. **Davison, H. C., J. C. Low, and M. E. Woolhouse.** 2000. What is antibiotic
337 resistance and how can we measure it? *Trends Microbiol* **8**:554-9.

338 7. **Delsol, A. A., M. Anjum, M. J. Woodward, J. Sunderland, and J. M. Roe.** 2003.
339 The effect of chlortetracycline treatment and its subsequent withdrawal on multi-
340 resistant *Salmonella enterica* serovar Typhimurium DT104 and commensal
341 *Escherichia coli* in the pig. *J Appl Microbiol* **95**:1226-34.

342 8. **Donaldson, S. C., B. A. Straley, N. V. Hegde, A. A. Sawant, C. DebRoy, and B. M.**
343 **Jayarao.** 2006. Molecular epidemiology of ceftiofur-resistant *Escherichia coli* isolates
344 from dairy calves. *Appl Environ Microbiol* **72**:3940-8.

345 9. **Escoula, L., M. Coste, and G. Larrieu.** 1982. Small filter membrane bags for the
346 study of antibiotic action in the digestive tract: bioavailability and in situ efficacy of
347 ampicillin in the pig caecum. *Res Vet Sci* **33**:338-42.

348 10. **FEDESA.** 2000. Press release on the European Union conference: The microbial
349 threat. Copenhagen, FEDESA.

350 11. **Funk, J. A., J. T. Lejeune, T. E. Wittum, and P. J. Rajala-Schultz.** 2006. The
351 effect of subtherapeutic chlortetracycline on antimicrobial resistance in the fecal flora
352 of swine. *Microb Drug Resist* **12**:210-8.

353 12. **Galtier, P., and J. Charpentreau.** 1979. Pharmacokinetics of ampicillin in pigs. *J. vet.*
354 *Pharmacol. Therap.* **2**:173-180.

355 13. **Gellin, G., B. E. Langlois, K. A. Dawson, and D. K. Aaron.** 1989. Antibiotic
356 resistance of gram-negative enteric bacteria from pigs in three herds with different
357 histories of antibiotic exposure. *Appl Environ Microbiol* **55**:2287-92.

358 14. **Hansen, W., and E. Yourassowsky.** 1984. Detection of beta-glucuronidase in
359 lactose-fermenting members of the family Enterobacteriaceae and its presence in
360 bacterial urine cultures. *J Clin Microbiol* **20**:1177-9.

361 15. **Harmoinen, J., S. Mentula, M. Heikkila, M. van der Rest, P. J. Rajala-Schultz, C.**
362 **J. Donskey, R. Frias, P. Koski, N. Wickstrand, H. Jousimies-Somer, E.**
363 **Westermarck, and K. Lindevall.** 2004. Orally administered targeted recombinant
364 Beta-lactamase prevents ampicillin-induced selective pressure on the gut microbiota: a
365 novel approach to reducing antimicrobial resistance. *Antimicrob Agents Chemother*
366 **48**:75-9.

367 16. **Heritage, J., N. Ransome, P. A. Chambers, and M. H. Wilcox.** 2001. A comparison
368 of culture and PCR to determine the prevalence of ampicillin-resistant bacteria in the
369 faecal flora of general practice patients. *J Antimicrob Chemother* **48**:287-9.

- 370 17. **Jensen, G. M., J. Lykkesfeldt, K. Frydendahl, K. Moller, and O. Svendsen.** 2004.
371 Pharmacokinetics of amoxicillin after oral administration in recently weaned piglets
372 with experimentally induced *Escherichia coli* subtype O149:F4 diarrhea. *Am J Vet*
373 *Res* **65**:992-5.
- 374 18. **Kung, K., B. R. Hauser, and M. Wanner.** 1995. Effect of the interval between
375 feeding and drug administration on oral ampicillin absorption in dogs. *J Small Anim*
376 *Pract* **36**:65-8.
- 377 19. **Livermore, D. M., F. Moosdeen, M. A. Lindridge, P. Kho, and J. D. Williams.**
378 1986. Behaviour of TEM-1 beta-lactamase as a resistance mechanism to ampicillin,
379 mezlocillin and azlocillin in *Escherichia coli*. *J Antimicrob Chemother* **17**:139-46.
- 380 20. **Maeda, H., C. Fujimoto, Y. Haruki, T. Maeda, S. Kokeyuchi, M. Petelin, H. Arai,**
381 **I. Tanimoto, F. Nishimura, and S. Takashiba.** 2003. Quantitative real-time PCR
382 using TaqMan and SYBR Green for *Actinobacillus actinomycetemcomitans*,
383 *Porphyromonas gingivalis*, *Prevotella intermedia*, tetQ gene and total bacteria. *FEMS*
384 *Immunol Med Microbiol* **39**:81-6.
- 385 21. **Mentula, S., T. Virtanen, A. Kanervo-Nordstrom, J. Harmoinen, E.**
386 **Westermarck, M. Rautio, P. Huovinen, and E. Kononen.** 2006. Relatedness of
387 *Escherichia coli* strains with different susceptibility patterns isolated from beagle dogs
388 during ampicillin treatment. *Int J Antimicrob Agents* **27**:46-50.
- 389 22. **NCCLS.** 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that
390 grow aerobically; Approved standard-Sixth Edition - Document M7-A6. NCCLS,
391 Wayne, PA.
- 392 23. **NCCLS.** 2003. Performance Standards for Antimicrobial Susceptibility Testing;
393 Thirteenth Informational Supplement- Document M100-S13 (M7) for use with
394 document M7-A6-MIC testing. NCCLS, Wayne, PA.
- 395 24. **Paterson, D. L.** 2006. Resistance in gram-negative bacteria: Enterobacteriaceae. *Am J*
396 *Infect Control* **34**:S20-8; discussion S64-73.
- 397 25. **Paterson, D. L., and R. A. Bonomo.** 2005. Extended-spectrum beta-lactamases: a
398 clinical update. *Clin Microbiol Rev* **18**:657-86.
- 399 26. **Phillips, I.** 1998. The 1997 Garrod Lecture. The subtleties of antibiotic resistance. *J*
400 *Antimicrob Chemother* **42**:5-12.
- 401 27. **Phillips, I., M. Casewell, T. Cox, B. De Groot, C. Friis, R. Jones, C. Nightingale,**
402 **R. Preston, and J. Waddell.** 2004. Does the use of antibiotics in food animals pose a
403 risk to human health? A critical review of published data. *J Antimicrob Chemother*
404 **53**:28-52.
- 405 28. **Poole, K.** 2004. Resistance to beta-lactam antibiotics. *Cell Mol Life Sci* **61**:2200-23.
- 406 29. **Salyers, A. A., A. Gupta, and Y. Wang.** 2004. Human intestinal bacteria as
407 reservoirs for antibiotic resistance genes. *Trends Microbiol* **12**:412-6.
- 408 30. **Sawant, A. A., N. V. Hegde, B. A. Straley, S. C. Donaldson, B. C. Love, S. J.**
409 **Knabel, and B. M. Jayarao.** 2007. Antimicrobial-resistant enteric bacteria from dairy
410 cattle. *Appl Environ Microbiol* **73**:156-63.
- 411 31. **Smith, M. S., R. K. Yang, C. W. Knapp, Y. Niu, N. Peak, M. M. Hanfelt, J. C.**
412 **Galland, and D. W. Graham.** 2004. Quantification of tetracycline resistance genes in
413 feedlot lagoons by real-time PCR. *Appl Environ Microbiol* **70**:7372-7.
- 414 32. **Sorum, H., and M. Sunde.** 2001. Resistance to antibiotics in the normal flora of
415 animals. *Vet Res* **32**:227-41.
- 416 33. **Sullivan, A., C. Edlund, and C. E. Nord.** 2001. Effect of antimicrobial agents on the
417 ecological balance of human microflora. *Lancet Infect Dis* **1**:101-14.
- 418 34. **Sunde, M., K. Fossum, A. Solberg, and H. Sorum.** 1998. Antibiotic resistance in
419 *Escherichia coli* of the normal intestinal flora of swine. *Microb Drug Resist* **4**:289-99.

- 420 35. **Tenover, F. C.** 1989. DNA probes for antimicrobial susceptibility testing. *Clin Lab*
421 *Med* **9**:341-7.
- 422 36. **Welling, P. G.** 1989. Effects of food on drug absorption. *Pharmacol Ther* **43**:425-41.
- 423 37. **Wiuiff, C., J. Lykkesfeldt, O. Svendsen, and F. M. Aarestrup.** 2003. The effects of
424 oral and intramuscular administration and dose escalation of enrofloxacin on the
425 selection of quinolone resistance among *Salmonella* and coliforms in pigs. *Res Vet Sci*
426 **75**:185-93.
- 427 38. **Yan, S. S., and J. M. Gilbert.** 2004. Antimicrobial drug delivery in food animals and
428 microbial food safety concerns: an overview of in vitro and in vivo factors potentially
429 affecting the animal gut microflora. *Adv Drug Deliv Rev* **56**:1497-521.
- 430 39. **Yu, Z., F. C. Michel, Jr., G. Hansen, T. Wittum, and M. Morrison.** 2005.
431 Development and application of real-time PCR assays for quantification of genes
432 encoding tetracycline resistance. *Appl Environ Microbiol* **71**:6926-33.

433
434

FIGURE LEGENDS

435 FIG. 1. Standard curves calculated with the control plasmid diluted in Tris -EDTA buffer (●)
436 or in DNA extracted from swine feces (◆). Amplification was repeated four times for each
437 dilution.

438

439 FIG. 2. a) Percentage of ampicillin resistant *Enterobacteriaceae* for each mode of ampicillin
440 administration. These percentages were calculated from the total counts of
441 *Enterobacteriaceae* in the absence or presence of ampicillin (16 µg/mL). b) Percentage of
442 ampicillin-resistant *E. coli* (i.e. with MIC above 16 µg/mL), for each mode of ampicillin
443 administration. Ampicillin susceptibility was tested at each sampling point on 20 isolates
444 from each pig. Treated pigs had received ampicillin at 20 mg/kg from day 0 to day 6 by
445 intramuscular route (▲) (n=4), oral route in fasted (■) (n=4) or fed (□) (n=4) pigs. 6 pigs
446 were used as a control (●). Values are means and error bars represent standard deviations.

447

448 FIG. 3. Copy number of *bla*_{TEM} genes per g of feces detected by real-time PCR for each pig.
449 Ampicillin was administered at 20 mg/kg from day 0 to day 6. Modes of administration were:
450 a) oral route in fed pigs (n=4), b) oral route in fasted pigs (n=4), c) intramuscular route (n=4).
451 d) 6 pigs were used as a control.


452

453 FIG. 4. Copy number of *bla*_{TEM} genes per g of feces for each mode of ampicillin
454 administration. Treated pigs had received ampicillin at 20 mg/kg from day 0 to day 6 by
455 intramuscular route (▲) (n=4), oral route in fasted (■) (n=4) or fed (□) (n=4) pigs. 6 pigs
456 were used as a control (●). Values are means and error bars represent standard deviations.

457


458 FIG. 5. Relationship between the log of the *bla*_{TEM} copy number/g feces and the log of counts
459 of ampicillin-resistant *Enterobacteriaceae* /g of feces.
460

461 FIGURE 1
462




463
464
465

466 FIGURE 2
467




468
469
470
471

472 FIGURE 3
473




474
475

476 FIGURE 4
477



478
479
480

481 FIGURE 5
482



483
484

485